asco.org1 天
Characterization of visits to the emergency room by patients with colorectal cancer in the ...
A. Time interval between first visit to ER to diagnosis. B. Number of visits to ER in the year before CRC diagnosis.
asco.org16 天
Grants & Awards
Conquer Cancer®, the ASCO Foundation, has a mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Through our Grants & Awards Program, we are ...
asco.org2 天
Washington University experience with FOLFIRINOX in pancreatic cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org11 天
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org2 天
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Stability of rare TP53 co-mutations in AML patients.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org13 天
For PR Professionals
This page contains important information for corporate and institutional public relations professionals about ASCO Meetings. Once an abstract is submitted to an ASCO Meeting, the abstract and study ...
asco.org4 天
The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...